The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Nuclear factor kappa B (NF-κB) signaling is crucial in cancer initiation and progression.
• Constitutive NF-κB activation contributes to major hallmarks of malignancy, including proliferation, inflammation, and metastasis.
• NF-κB is a promising therapeutic target for various cancers and non-malignant diseases.

Purpose of the Study:

• To review strategies for overcoming toxicities associated with conventional NF-κB inhibitors.
• To highlight novel therapeutic approaches targeting oncogenic NF-κB signaling.

Main Methods:

• Discussion of strategies targeting upstream regulators of NF-κB.
• Review of agents targeting downstream effectors of NF-κB.
• Exploration of therapies targeting individual NF-κB subunits.

Main Results:

• Conventional NF-κB inhibitors face challenges due to on-target toxicities.
• Emerging strategies focus on circumventing systemic NF-κB blockade limitations.
• New molecules target specific components of the NF-κB pathway for improved safety and efficacy.

Conclusions:

• Developing clinically useful NF-κB inhibitors for cancer treatment remains a significant challenge.
• Targeting upstream regulators, downstream effectors, or individual subunits offers promising avenues.
• Novel therapeutic strategies are essential to harness the potential of NF-κB inhibition in oncology.